NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Clinical trials for NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED explained in plain language.
Never miss a new study
Get alerted when new NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED trials appear
Sign up with your email to follow new studies for NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Dual-Targeting CAR t therapy aims to outperform standard treatment for blood cancer
Disease control Recruiting nowThis Phase 3 trial tests a new CAR T-cell therapy called ronde-cel, which targets two proteins (CD19 and CD20) on lymphoma cells, against the standard single-target CAR T therapy. The study involves 400 adults with large B-cell lymphoma that has returned or not responded after in…
Matched conditions: NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated May 26, 2026 05:39 UTC
-
New combo therapy offers hope for patients with resistant lymphomas
Disease control Recruiting nowThis study tests whether adding ruxolitinib to the immunotherapy drug pembrolizumab is safe and effective for people with certain lymphomas that have come back or not responded to treatment. About 53 adults with Hodgkin or non-Hodgkin lymphoma will receive the combination. The go…
Matched conditions: NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED
Phase: PHASE2 • Sponsor: Seda S. Tolu • Aim: Disease control
Last updated May 20, 2026 11:56 UTC